Webinar Date/Time: Wed, Mar 19, 2025 1:00 PM EDT
Join Dikran Khachadourian as he introduces the Aura PTx platform, a groundbreaking tool from Halo Labs that uses advanced imaging and fluorescence microscopy to streamline protein stability studies. Discover how this low-volume, high-throughput system accelerates biologics development by rapidly sizing, counting, and characterizing proteins, particles, and more in mixed samples.
Register Free: https://www.biopharminternational.com/bp_w/advanced-stability-studies
Event Overview:
The success of protein therapeutics depends on their efficacy, safety, and stability. Specifically, stability studies play a crucial role in identifying factors that lead to aggregation and degradation. Traditional methods for analyzing stability often require large sample volumes, are time-consuming, and lack reliability. In this webinar, Dikran Khachadourian will introduce Halo Labs’ innovative Aura® PTx platform, which uses advanced imaging and fluorescence microscopy to rapidly size, count, and characterize proteins and other particles in mixed samples with minimal volumes. Attendees will explore its key applications, including developability assessments and USP788 testing.
Key Learning Objectives:
Who Should Attend:
Speaker:
Dikran Khachadourian
Field Application Scientist
Halo Labs
Dikran Khachadourian is a field application scientist at Halo Labs. Khachadourian completed his undergraduate studies at UC San Diego, obtaining a bachelor's degree in biochemistry and cell biology. His interest in the biological sciences led him to pursue a master’s degree in biology. After spending time in academia as a graduate researcher and educator, Khachadourian joined the Halo Labs team to apply his background to the ongoing advancements in biotechnology.
Register Free: https://www.biopharminternational.com/bp_w/advanced-stability-studies
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.